Literature DB >> 24492143

Allogeneic hematopoietic cell transplantation may alleviate the negative prognostic impact of monosomal and complex karyotypes on patients with acute myeloid leukemia.

Robert J Guo1, Eshetu G Atenafu2, Ken Craddock1, Hong Chang3.   

Abstract

Monosomal karyotype (MK) and complex karyotype (CK) are well known to be associated with a very poor clinical outcome in patients with acute myeloid leukemia (AML). However, whether or not the prognostic impact of MK and CK remains relevant for patients who have undergone allogeneic hematopoietic cell transplantation (allo-HCT) is still unclear. We retrospectively analyzed the status of MK and CK, as well as other clinical laboratory features, in 148 allo-HCT AML patients at our institution and correlated with their event-free survival (EFS) and overall survival (OS) after transplantation. MK and CK were identified in 14 (9%) and 19 (13%) cases, respectively. On univariate analysis, only age (≥60 years) and WBC count (≥15 × 10(9)/L) were significant adverse predictors for EFS (P < .001 and P = .017, respectively) and OS (P = .002 and P = .021, respectively). MK, CK, and other relevant parameters analyzed did not affect the clinical outcome. Multivariable analysis confirmed that both older age and high WBC count were independent prognostic factors for a shorter OS (P = .001 and P = .003, respectively) and a shorter EFS (P < .001 and P = .001, respectively). Our results indicate that neither MK nor CK are high-risk factors in AML patients undergoing allo-HCT.
Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Acute myeloid leukemia; Allogeneic stem cell transplantation; Complex karyotype; Cytogenetics; Immunophenotyping; Monosomal karyotype; Prognosis

Mesh:

Substances:

Year:  2014        PMID: 24492143     DOI: 10.1016/j.bbmt.2014.01.027

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  7 in total

1.  Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis.

Authors:  Armin Rashidi; Maryam Ebadi; Graham A Colditz; John F DiPersio
Journal:  Biol Blood Marrow Transplant       Date:  2015-10-31       Impact factor: 5.742

2.  Long-term follow-up of therapy-related myelodysplasia and AML patients treated with allogeneic hematopoietic cell transplantation.

Authors:  J Finke; C Schmoor; H Bertz; R Marks; R Wäsch; R Zeiser; B Hackanson
Journal:  Bone Marrow Transplant       Date:  2016-01-11       Impact factor: 5.483

3.  Allogeneic Hematopoietic Cell Transplantation for Older Patients: Prognosis Determined by Disease Risk Index.

Authors:  Fiona He; Qing Cao; Aleksandr Lazaryan; Claudio Brunstein; Shernan Holtan; Erica Warlick; Celalettin Ustun; Brian McClune; Mukta Arora; Armin Rashidi; Craig Eckfeldt; Daniel J Weisdorf; Nelli Bejanyan
Journal:  Biol Blood Marrow Transplant       Date:  2017-05-15       Impact factor: 5.742

4.  Allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia: similar outcomes regardless of donor type.

Authors:  Erica D Warlick; Regis Peffault de Latour; Ryan Shanley; Marie Robin; Nelli Bejanyan; Alienor Xhaard; Claudio Brunstein; Flore Sicre de Fontbrune; Celalettin Ustun; Daniel J Weisdorf; Gerard Socie
Journal:  Biol Blood Marrow Transplant       Date:  2014-11-06       Impact factor: 5.742

5.  Monosomal karyotype as an adverse prognostic factor in patients with acute myeloid leukemia treated with allogeneic hematopoietic stem-cell transplantation in first complete remission: a retrospective survey on behalf of the ALWP of the EBMT.

Authors:  Angelique V M Brands-Nijenhuis; Myriam Labopin; Harry C Schouten; Liisa Volin; Gérard Socié; Jan J Cornelissen; Anne Huynh; Per Ljungman; Florent Malard; Jordi Esteve; Arnon Nagler; Mohamad Mohty
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

6.  Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004.

Authors:  M Rasche; C von Neuhoff; M Dworzak; J-P Bourquin; J Bradtke; G Göhring; G Escherich; G Fleischhack; N Graf; B Gruhn; O A Haas; T Klingebiel; B Kremens; T Lehrnbecher; A von Stackelberg; J Tchinda; Z Zemanova; C Thiede; N von Neuhoff; M Zimmermann; U Creutzig; D Reinhardt
Journal:  Leukemia       Date:  2017-04-25       Impact factor: 11.528

7.  Impact of pretransplant measurable residual disease on the outcome of allogeneic hematopoietic cell transplantation in adult monosomal karyotype AML.

Authors:  Linde M Morsink; Megan Othus; Evandro D Bezerra; Brent L Wood; Min Fang; Brenda M Sandmaier; Marco Mielcarek; Gary Schoch; Rainer Storb; H Joachim Deeg; Frederick R Appelbaum; Roland B Walter
Journal:  Leukemia       Date:  2020-01-23       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.